Ms. Shierley Widjaja is an Executive Director and Chief Investment Officer of SJE Investments, the family office of Mr. Franky Widjaja, the Chief Executive Officer of Golden Agri Resources. SJE invests in a broad range of asset classes including public equity, fixed income, private companies, and alternatives such as venture capital and hedge funds. Prior to starting SJE Investments, Ms. Widjaja was a Portfolio Manager at McKinley Capital Management, specializing in global growth equity strategies. She started her career as an Analyst at UBS Investment Bank in Hong Kong, specializing in Mergers and Acquisitions. Ms. Widjaja obtained her Master of Business Administration from the Wharton School, University of Pennsylvania with a Finance and Accounting concentration. Ms. Widjaja graduated from University of California Los Angeles, Summa Cum Laude, with a Bachelor of Science in Electrical Engineering.
Adam joined Prometheus’ board of directors in November 2020 and is currently Chief Investment Officer of Perceptive. Prior to Perceptive he was a senior analyst at Ursus Capital. During his five years there he focused on biotech and specialty pharmaceuticals. He graduated, with honors, from Princeton University with a B.A. in molecular biology. Adam serves on the board of directors for several of Perceptive’s portfolio companies, including Solid Biosciences, Renovia, and Xontogeny. Additionally, Adam serves as the CEO of ARYA Sciences Acquisition Corp, and he is a member of Perceptive’s internal investment committees for the credit opportunities and venture funds.
Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011 he became a tenured Professor of Medicine and Adjunct Professor of Surgery at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System. He was previously a co-founder of Santarus working directly with Scott Glenn, Stephan Targan & Gerry Proehl. Dr. Sandborn has published over 720 peer reviewed articles and is a member of the editorial board for the New England Journal of Medicine.
Mr. Papa has more than 35 years of experience in the pharmaceutical, healthcare services and specialty pharmaceutical industries, including 20 years of branded prescription drug experience. Mr. Papa currently serves as Chairman and Chief Executive Officer of Bausch Health, a recognized global healthcare company. Prior to Bausch Health, Mr. Papa was Chief Executive Officer and Chairman of the Board of Directors of Perrigo, a self-care products company, where he grew the company into a global leader with annual net sales of more than $5 billion. Prior to Perrigo, Mr. Papa served as Chairman and Chief Executive Officer of the Pharmaceutical and Technologies Services segment of Cardinal Health, Inc., President and Chief Operating Officer of Watson Pharmaceuticals, President of Global Country Operations for Pharmacia’s North American business and President of Searle’s U.S. Operations. Prior to Searle/Pharmacia, Mr. Papa served in a variety of general management, sales, marketing and research and development positions during his 15-year career at Novartis Pharmaceuticals. During his pharmaceutical industry career, he led teams that successfully launched several blockbuster pharmaceutical products including Lotrel, Diovan and Celebrex, and is the patent holder for a cardiovascular combination treatment containing Amlodipine and Benazepril. In October 2014, Harvard Business Review ranked Mr. Papa 47th on its “2014 Best Performing CEOs in the World.” Mr. Papa holds a BS in pharmacy from the University of Connecticut and an MBA from Northwestern University’s Kellogg Graduate School of Management. In 2012, he received an Honorary Doctor of Science degree from the University of Connecticut School of Pharmacy.
James Laur is vice president, Intellectual Property and heads up Cedars-Sinai Technology Ventures reporting to the health system’s chief financial officer. Mr. Laur’s primary responsibilities are focused on innovation, technology transfer and international business activities. He drives new business development and investment opportunities involving innovation and technology-related activities at Cedars-Sinai and its global partners. Laur serves as co-executive sponsor of the Cedars-Sinai Accelerator Program and also represents Cedars-Sinai on the board of directors of some of its spinoff companies and other investments. He holds dual bachelor’s degrees, with honors, from UCLA in political science and philosophy. He earned his doctorate of law degree, cum laude, from the Boston College Law School.
Joy joined Prometheus’ board of directors in November 2020 and he currently serves as a Senior Research Analyst at Eventide, with a primary focus on healthcare and life sciences.
Dr. Ghosh has a cross-disciplinary background in biopharma/biotech R&D, business development/M&A, and healthcare investing. Prior to joining Eventide, from 2017-2020, Dr. Ghosh was an Associate/Vice President at Bain Capital for their Life Sciences Fund. From 2016-2017, Dr. Ghosh was a Sr. Manager at Biogen. From 2009-2016, Dr. Ghosh was an Investigator at the Novartis Institutes of Biomedical Research. Prior to Novartis, Dr. Ghosh was a postdoctoral scientist at Brigham and Women’s Hospital/Harvard Medical School and Boston University School of Medicine.
He holds a PhD from the University of Washington, Seattle in Biomolecular Structure and Design and a bachelor’s degree from the University of Texas at Austin in Biochemistry.
Mr. McKenna serves as President, CEO and member of the board of Prometheus Biosciences. Prior to joining Prometheus Biosciences, Mr. McKenna was President & CEO of Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies. He joined Salix in March 2016 as the Senior Vice President and General Manager, responsible for the company’s gastrointestinal franchise. During his tenure, Mr. McKenna successfully led the company through a series of key strategic acquisitions, the launch of a number of new products, and delivered strong operating performance, with revenue increasing from $1.2B to $2B. Prior to joining Salix, Mr. McKenna spent more than a decade with Bausch + Lomb, most recently as Senior Vice President/General Manager of its U.S. Vision Care business. Prior to Bausch + Lomb, Mark held several roles of increasing responsibility at Johnson & Johnson. Mark holds a B.S. in Marketing from Arizona State University, an MBA from Azusa Pacific University and is a Fellow with the University of Pennsylvania, Wharton School of Business.
Dr. Tadataka (Tachi) Yamada is currently a Venture Partner with Frazier Healthcare Partners and Chairman of the Board of Directors at Prometheus Biosciences. Prior to joining Frazier, he was Executive Vice-President, Chief Medical and Scientific Officer and a Board Member of Takeda Pharmaceuticals. He was formerly President of the Bill & Melinda Gates Foundation Global Health Program. In this capacity he oversaw grants totaling over $9 billion in programs directed at applying technologies to address major health challenges of the developing world including TB, HIV, malaria and other infectious diseases, malnutrition and maternal and child health. He was previously Chairman of R&D at GlaxoSmithKline and before that Chairman of the Department of Internal Medicine and Physician-in-Chief at the University of Michigan Medical Center.